SOLASTA Bio is thrilled to announce significant progress in its mission to transform the crop protection industry with its innovative peptide solutions. The company has secured Series A funding, an essential milestone in its journey to address the pressing challenges of traditional insect control agents.

Joy Faucher, Partner at Forbion’s BioEconomy Fund, highlighted the significance of this development, stating, “As traditional insect control agents face issues with resistance and biodiversity impact, SOLASTA’s cost-effective, sustainable, and high-efficacy solution is set to revolutionize the crop protection market. We are excited to support SOLASTA in advancing the development and commercialization of its first-in-class peptide products.”

Dr. Shireen Davies, CEO and co-founder of SOLASTA Bio, shared her enthusiasm for the progress made over the past three years. “We have come a long way since we embarked on this journey. We’ve developed a unique technology platform to address grower pain points, expanded operations to the US, and assembled a team with outstanding expertise in technology and agribusiness. The results of our field trials have been incredibly promising, demonstrating that our biopeptides are as effective, if not more so, than traditional insecticides against target pests.”

With the infusion of Series A funding, SOLASTA Bio is poised to elevate its operations to the next level. The focus will be on accelerating the commercialization of their groundbreaking peptide products, which promise to deliver high efficacy and sustainability in crop protection.

For more updates on SOLASTA Bio’s progress and its innovative solutions in the crop protection sector, visit SOLASTA Bio’s website.

Read The Full Article Here – Solasta Bio